Current approvals concern specific structural or genetic causes, with product-specific labeling.
HormonalHormone
TRT
Testosterone replacement therapy
Studied forDiagnosed testosterone deficiency4
FDA-approved products treat specified forms of male hypogonadism. The April 2026 announcement invited applications for a possible new indication; it did not approve it.
What does it do?
Testosterone replacement treats diagnosed hypogonadism; it is hormone therapy, not a peptide or a generic wellness intervention.
Approved & studied uses
Community uses Reported, unvalidated
Restoration
16Testosterone normalization, sexual symptoms, mood and energy; fertility may be suppressed.
Composition / bone
16Lean mass, strength, fat and bone density.
Metabolic
16Insulin-sensitivity and cardiovascular research; benefit is not universal.
Reasons people report using it; these do not establish benefit.16
Evidence limits
View research →Trial results in selected hypogonadal men do not establish safety of supraphysiologic use or every formulation.3
5 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Blood pressure
FDA requires warnings about increased blood pressure.3
FDA-approved products treat specified forms of male hypogonadism. The April 2026 announcement invited applications for a possible new indication; it did not approve it.
Amino-acid sequence
Not applicable: this compound is not a single peptide.
Reference identity · not independently confirmed16
LengthSteroid hormone (not a peptide)
Molecular weight · Da288.4 Da
Formula, sequence notation & identity
Unesterified testosterone
TRT includes multiple formulations and esters; this is the parent hormone only.
Pep-Pedia identity details
Steroid hormone (not a peptide) · 412.61 Da (Cypionate) / 400.59 Da (Enanthate)
C27H40O3 (Cypionate) / C26H40O3 (Enanthate)Reference description; checked chemical identity above takes precedence when available.16
Pharmacokinetics
How long does it stay in the body?
Unverified reference estimateNot independently confirmed
Reference half-life5 days – 8 days15
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%–64.8%of reference level
Illustrative scenario using an unverified reference estimate. Shading shows the reported half-life range. No midpoint is assumed.
About 3% remaining after 25 d–40 d
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: FDA Depo-Testosterone label
Source’s reported peak time: 2 days. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Safety finding has boundaries
Noninferiority for the primary cardiovascular endpoint is not proof of risk-free treatment.5
Reported timelines
Reference & communitySource expectations
Symptoms 3–6 weeks; recovery 2–3 months; composition 3–6; bone 6–12. Route and diagnosis matter.16
These are reported timelines, not a prediction of your response.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Effectiveness
The source hides 8 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 10 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “712 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
FDA warning language has changed; blanket route-superiority/fertility claims are unsupported.
Route
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| TopicalTransdermal | 1.62% gel, adjusted to testosterone 350–750 ng/dL | Daily | Cardiovascular safety in hypogonadismHuman study | Mean treatment 21.7 months | 5 |
Population 5,246 men aged 45–80 with symptoms, two low fasting testosterone results and cardiovascular disease or risk Context Monitored clinical trial; not an injectable protocol. | |||||
| SubQSubcutaneous | 100-200 mg | Weekly or split 2x/week | Standard TRTReference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source route wording IM or SubQ Source tabs Injectable | |||||
| IMIntramuscular | 100-200 mg | Weekly or split 2x/week | Standard TRTReference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source route wording IM or SubQ Source tabs Injectable | |||||
| SubQSubcutaneous | 75-100 mgStarting dose | Weekly | Conservative StartReference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source route wording IM or SubQ Source tabs Injectable | |||||
| IMIntramuscular | 75-100 mgStarting dose | Weekly | Conservative StartReference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source route wording IM or SubQ Source tabs Injectable | |||||
| SubQSubQ preferred | 50-100 mg | Every 3.5 days | Stable Levels (Split)Reference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Injectable | |||||
| SubQSubcutaneous | 100-150 mg + 250-500 IU hCG | T weekly, hCG 2-3x/week | With hCG (Fertility)Reference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source route wording IM/SubQ + SubQ Source tabs Injectable | |||||
| IMIntramuscular | 100-150 mg + 250-500 IU hCG | T weekly, hCG 2-3x/week | With hCG (Fertility)Reference report | Ongoing lifetime therapy for diagnosed hypogonadism | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source route wording IM/SubQ + SubQ Source tabs Injectable | |||||
| OralOral (with fat-containing meal) | 237 mg | Twice daily with food | Jatenzo StandardReference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Oral | |||||
| OralOral (titrate based on levels) | 158-396 mg | Twice daily | Jatenzo Dose RangeReference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Oral | |||||
| Oral | 225 mg | Twice daily with food | TLANDOReference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Oral | |||||
| OtherShoulders, upper arms | 50-100 mg | Once daily | AndroGel 1%Reference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Topical | |||||
| OtherShoulders, upper arms | 40.5-81 mg | Once daily | AndroGel 1.62%Reference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Topical | |||||
| OtherShoulders, upper arms | 50-100 mg | Once daily | Testim 1%Reference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Topical | |||||
| OtherScrotum or shoulders | 100-200 mg | Once or twice daily | Compounded CreamReference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Topical | |||||
| IntranasalNasal | 11 mg per nostril | 3x daily (every 6-8 hours) | Standard NatestoReference report | Ongoing therapy | 16 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. FDA warning language has changed; blanket route-superiority/fertility claims are unsupported. Source tabs Nasal | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Ongoing lifetime therapy for diagnosed hypogonadism
- Break
- Not applicable - continuous therapy (stopping causes symptoms to return)
Reported timing
Consistent day(s) weekly; morning injection mimics natural rhythm
Oral
- Use period
- Ongoing therapy
- Break
- Not applicable
Reported timing
With breakfast and dinner
Topical
- Use period
- Ongoing therapy
- Break
- Not applicable
Reported timing
Morning after showering, allow to dry completely
Nasal
- Use period
- Ongoing therapy
- Break
- Not applicable
Reported timing
Morning, afternoon, evening - spaced ~6 hours apart
Side effects & safety
Blood pressure
FDA requires warnings about increased blood pressure.
3Other adverse outcomes
TRAVERSE observed more atrial fibrillation, kidney injury and pulmonary embolism.
5Population limitation
These findings do not validate unmonitored or supraphysiologic use.
5Monitoring
BP, hematocrit and clinically appropriate prostate/hormone assessment; infertility, edema, acne/hair and sleep-apnea concerns.
Route risks
Skin transfer to contacts; flammable gels; nasal injury; oral absorption/product instructions differ.
Urgent
VTE symptoms, dyspnea/edema, major mood/BP changes, high hematocrit, severe local reactions or household virilization.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Insulin
Caution reportedGlucose effects.16
Reference report · Pep-Pedia label: Monitor CombinationAnticoagulants
Caution reportedAnticoagulant response may change.16
Reference report · Evidence context: Monitor combinationhCG
Unverified pairingFertility strategy needs specialist care.16
Reference report · Pep-Pedia label: SynergisticAnastrozole
Unverified pairingNot routinely required.16
Reference report · Evidence context: SupportiveGH peptides
Unverified pairingUnproven body-composition stack.16
Reference report · Evidence context: SynergisticClomiphene
Unverified pairingNot interchangeable treatment.16
Reference report · Evidence context: AlternativeOther medicines
Not establishedA class-level profile cannot replace the interaction section for the prescribed product.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
Approved products include gels and prepared injections. A generic peptide reconstitution recipe does not apply.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
The source discusses finished testosterone products; preparation depends on the exact presentation.
- Form
- Source describes a prepared product
- Reported parameters
- Injectable oil, oral products and topical products are not interchangeable.
The site repeats oil-injection instructions across route tabs, including nasal. That repetition does not define route-specific handling.
Oral
The source discusses finished testosterone products; preparation depends on the exact presentation.
- Form
- Source describes a prepared product
- Reported parameters
- Injectable oil, oral products and topical products are not interchangeable.
The site repeats oil-injection instructions across route tabs, including nasal. That repetition does not define route-specific handling.
Topical
The source discusses finished testosterone products; preparation depends on the exact presentation.
- Form
- Source describes a prepared product
- Reported parameters
- Injectable oil, oral products and topical products are not interchangeable.
The site repeats oil-injection instructions across route tabs, including nasal. That repetition does not define route-specific handling.
Nasal
The source discusses finished testosterone products; preparation depends on the exact presentation.
- Form
- Source describes a prepared product
- Reported parameters
- Injectable oil, oral products and topical products are not interchangeable.
The site repeats oil-injection instructions across route tabs, including nasal. That repetition does not define route-specific handling.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearancePharmaceutical Grade ProductReported appearanceClear Oil SolutionReported appearanceProper Storage VerificationReported variationCompounded TestosteroneReported concernUnderground Lab (UGL) ProductsReported concernCrystallized or Cloudy Solution
16Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
No applicable mixing data
The available sources describe prepared products or do not establish a reconstitution method.16
Full storage notes from Pep-Pedia
16Room temperature 20-25°C (68-77°F). Do not refrigerate or freeze.
Room temperature
Room temperature, away from heat and flame (flammable alcohol content)
Room temperature, upright position
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Research findings
Human trialsSource context
FDA warning language has changed; blanket route-superiority/fertility claims are unsupported.
Compound identity & other names
TRT is testosterone replacement therapy, not a peptide. Evidence, absorption, adverse effects and preparation depend on the prescribed formulation and the reason for treatment.
FDA-approved products treat specified forms of male hypogonadism. The April 2026 announcement invited applications for a possible new indication; it did not approve it.
How it may work
Androgen-receptor signaling; injection esters, oral undecanoate, skin and nasal products have different exposure profiles.16
Safety labeling changed in 2025
FDA removed cardiovascular-outcome boxed-warning language after reviewing TRAVERSE, while requiring warnings that testosterone products can increase blood pressure.
32026 announcement is not a new approval
FDA encouraged applications for low libido with idiopathic hypogonadism; substantial evidence is still required before approval.
4TRAVERSE defines a specific population
Major cardiovascular events occurred in 7.0% versus 7.3% with placebo, meeting noninferiority. Higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism remained relevant.
5Source checks & newer research
FDA testosterone labeling changes
February 2025: removed boxed-warning language about increased adverse cardiovascular outcomes and required increased-BP warnings. This does not establish risk-free therapy or every route’s equivalence to TRAVERSE gel.
Regulatory update17FDA current testosterone information
FDA reports June 2026 requested updates removing the age-related-hypogonadism limitation of use and revising prostate/BPH safety language. Indications and contraindications still require the current specific product label.
Regulatory update18Research areas and evidence gaps
Specified male hypogonadism. Current approvals concern specific structural or genetic causes, with product-specific labeling.4
- Trial results in selected hypogonadal men do not establish safety of supraphysiologic use or every formulation.
- A product-specific research-vial quantity was not independently verified in this review.
Community reports Unvalidated
Pep-Pedia discusses diagnosed hypogonadism.7
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
Added 2025 labeling changes and the April 2026 indication-development announcement; the latter is not a new approval.
- Checked
- 2026-10-12
- Search
- testosterone replacement 2025 2026 FDA blood pressure TRAVERSE
- Catalog
- Pep-Pedia ↗ · 9 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1TRAVERSE Cardiovascular Safety Trial (2023)Abstract checked
AI-PREPARED SUMMARY
TRAVERSE found transdermal testosterone noninferior to placebo for major cardiovascular events in selected hypogonadal men with cardiovascular risk. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often.
Pep-Pedia bibliography · Checked 2026-10-12
2Cardiovascular Safety of Testosterone-Replacement TherapyAbstract checked
AI-PREPARED SUMMARY
TRAVERSE found transdermal testosterone noninferior to placebo for major cardiovascular events in selected hypogonadal men with cardiovascular risk. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often.
Pep-Pedia bibliography · Checked 2026-10-12
3FDA issues class-wide labeling changes for testosterone productsPrimary source checked
AI-PREPARED SUMMARY
FDA removed the cardiovascular-outcome boxed-warning language following TRAVERSE, retained age-related limitations of use, and required blood-pressure warnings.
Safety labeling changed in 2025
FDA removed cardiovascular-outcome boxed-warning language after reviewing TRAVERSE, while requiring warnings that testosterone products can increase blood pressure.
Additional research · Checked 2026-10-12
4FDA Takes Step Forward on Testosterone Therapy for MenPrimary source checked
AI-PREPARED SUMMARY
FDA invited applications for a potential new low-libido indication in idiopathic hypogonadism. The announcement is not an approval of that indication.
2026 announcement is not a new approval
FDA encouraged applications for low libido with idiopathic hypogonadism; substantial evidence is still required before approval.
Additional research · Checked 2026-10-12
5Cardiovascular Safety of Testosterone-Replacement TherapyAbstract checked
AI-PREPARED SUMMARY
TRAVERSE found transdermal testosterone noninferior to placebo for major cardiovascular events in selected hypogonadal men with cardiovascular risk. Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often.
TRAVERSE defines a specific population
Major cardiovascular events occurred in 7.0% versus 7.3% with placebo, meeting noninferiority. Higher rates of atrial fibrillation, acute kidney injury and pulmonary embolism remained relevant.
Additional research · Checked 2026-10-12
6PubChem: TestosteronePrimary source checked
AI-PREPARED SUMMARY
Chemical identity of unesterified testosterone; injectable esters are different chemical entities.
Additional research · Checked 2026-10-12
7Pep-Pedia: TRTCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
8Testosterone Trials - Body Composition (2017)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Older hypogonadal men had improvements in some sexual, mood and physical measures; effects varied by endpoint and trial subgroup.
Reported population / model
788 men ≥65 years
Reported study details
1 year · Multiple endpoints
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Meta-Analysis: Muscular Responses to TRT (2018)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Pooled studies reported greater fat-free-mass and strength changes with intramuscular than transdermal treatment; formulation comparisons may be confounded.
Reported population / model
31 RCTs analyzed
Reported study details
Various formulations · Fat-free mass outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
10Long-Term Safety Registry Study (2016)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Registry participants had sustained metabolic/body-composition changes; observational follow-up cannot by itself establish long-term causal safety.
Reported population / model
1,000+ men
Reported study details
Up to 12 years · Real-world outcomes
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
11Effects of Testosterone Treatment in Older MenPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Older hypogonadal men had improvements in some sexual, mood and physical measures; effects varied by endpoint and trial subgroup.
Reported population / model
788 men ≥65 years
Reported study details
1 year · Multiple endpoints
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12Testosterone supplementation and body composition: meta-analysis of observational studiesLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
13Testosterone Therapy in Men With Hypogonadism: Endocrine Society GuidelineLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
14Evaluation and Management of Testosterone Deficiency: AUA GuidelineLinked reference · Not independently reviewed
REFERENCE NOTE
Reference retained from Pep-Pedia’s bibliography; findings and bibliographic accuracy have not been independently verified.
Pep-Pedia bibliography · Checked 2026-10-12
15Pep-Pedia: TRT — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 5 days – 8 days and a peak time of 2 days. Stated attribution: FDA Depo-Testosterone label. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
16Pep-Pedia: TRT — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
17FDA testosterone labeling changesPrimary source checked
AI-PREPARED SUMMARY
February 2025: removed boxed-warning language about increased adverse cardiovascular outcomes and required increased-BP warnings. This does not establish risk-free therapy or every route’s equivalence to TRAVERSE gel.
FDA testosterone labeling changes
February 2025: removed boxed-warning language about increased adverse cardiovascular outcomes and required increased-BP warnings. This does not establish risk-free therapy or every route’s equivalence to TRAVERSE gel.
Additional primary-source check · Checked 2026-10-12
18FDA current testosterone informationPrimary source checked
AI-PREPARED SUMMARY
FDA reports June 2026 requested updates removing the age-related-hypogonadism limitation of use and revising prostate/BPH safety language. Indications and contraindications still require the current specific product label.
FDA current testosterone information
FDA reports June 2026 requested updates removing the age-related-hypogonadism limitation of use and revising prostate/BPH safety language. Indications and contraindications still require the current specific product label.
Additional primary-source check · Checked 2026-10-12